{"id":44426,"date":"2022-05-27T13:01:57","date_gmt":"2022-05-27T11:01:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/castle-biosciences-decisiondx-melanoma-test-receives-2022-medtech-breakthrough-award\/"},"modified":"2022-05-27T13:01:57","modified_gmt":"2022-05-27T11:01:57","slug":"castle-biosciences-decisiondx-melanoma-test-receives-2022-medtech-breakthrough-award","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/castle-biosciences-decisiondx-melanoma-test-receives-2022-medtech-breakthrough-award\/","title":{"rendered":"Castle Biosciences\u2019 DecisionDx\u00ae-Melanoma Test Receives 2022 MedTech Breakthrough Award"},"content":{"rendered":"
\n

\nThis is the second consecutive year that Castle has been recognized for its innovative solutions in dermatology<\/i>\n<\/p>\n

FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL<\/a> #CSTL<\/a>–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as the winner of the \u201cBest New Technology Solution \u2013 Dermatology\u201d award in the sixth annual MedTech Breakthrough Awards program for its innovative DecisionDx\u00ae-Melanoma gene expression profile (GEP) test. DecisionDx-Melanoma leverages Castle\u2019s advanced technologies to identify the risk of metastasis, recurrence and sentinel lymph node (SLN) positivity for patients diagnosed with invasive cutaneous melanoma. In 2021, Castle was awarded \u201cBest New Technology Solution \u2013 Oncology\u201d by MedTech Breakthrough for its DecisionDx\u00ae-SCC and DecisionDx\u00ae DiffDx\u00ae-Melanoma GEP tests, both of which were launched in the second half of 2020.\n<\/p>\n

<\/a><\/p>\n

\nThe mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories. This year\u2019s program attracted more than 3,900 nominations from over 15 different countries throughout the world.\n<\/p>\n

\nDecisionDx-Melanoma is Castle\u2019s proprietary risk stratification GEP test that is designed to use a patient\u2019s tumor biology to predict individual risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer, as well as the risk of SLN positivity, independent of traditional staging factors. Unlike traditional treatment plans that are developed using clinical and pathologic factors alone (e.g., a patient\u2019s age, tumor thickness, ulceration, etc.), incorporating the patient\u2019s primary tissue biology can help physicians and patients make more informed disease management decisions aligned with each patient\u2019s unique biologic risk.\n<\/p>\n

\n\u201cHaving an accurate picture of whether melanoma is likely to recur or spread is critical to making the right treatment and disease management decisions, and though risk indicators like clinicopathological factors and patient history are important, they have their limitations,\u201d said James Johnson, managing director, MedTech Breakthrough. \u201cGenomic testing can supplement these traditional factors, and Castle\u2019s GEP test has been shown to accurately and independently predict individual risk of recurrence or metastasis, and can provide clinically actionable and personalized information to inform the treatment plan for each patient. Congratulations to the Castle team for being our choice for \u2018Best New Technology Solution \u2013 Dermatology.\u2019\u201d\n<\/p>\n

\nIn 2021, Castle incorporated two new proprietary, independently validated algorithms into its DecisionDx-Melanoma test: i31-SLNB (designed to predict SLN positivity) and i31-ROR (designed to predict an individual patient\u2019s risk of recurrence). These algorithms combine a patient\u2019s clinical and pathologic risk factors with their DecisionDx-Melanoma class result to provide an Integrated Test Result with precise and personalized risk information specific to each patient, including his\/her:\n<\/p>\n